Advances in Diagnostics and Treatments for Glioblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 10 April 2026
Special Issue Editors
Interests: glioblastoma; next-generation-sequencing; targeted therapy; deep learning; immunotherapy
Special Issue Information
Dear Colleagues,
Glioblastoma is the most common and aggressive primary brain tumor in adults, characterized by rapid progression, profound intratumoral heterogeneity, and resistance to therapy. Despite advances in surgery, radiotherapy, and systemic treatments, overall survival remains limited. Recent progress in imaging, molecular profiling, and biomarker discovery is transforming our diagnostic capabilities and enabling more precise, individualized therapeutic strategies.
For this Special Issue, we invite high-quality original research, clinical trial reports, and comprehensive reviews on innovations in both diagnostics and treatment in glioblastoma. We particularly welcome contributions addressing integrated diagnostic approaches, predictive biomarkers, novel imaging modalities, targeted therapies, immunotherapy, and multidisciplinary treatment strategies aimed at improving patient outcomes.
Dr. Sied Kebir
Dr. Manmeet Singh Ahluwalia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- molecular diagnostics
- neuro-oncology
- imaging biomarkers
- immunotherapy
- targeted therapy
- tumor-treating fields
- radiotherapy
- chemotherapy
- translational research
- machine learning
- positron emission tomography
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
